zurück Home

Immuntherapie des NSCLC

Allgemeines

  
Pembrolizumab Pembrolizumab in Kombination mit
Pemetrexed und
Carboplatin (US-Zulassung)
  • NSCLC
  • nicht-SCC
  • metastasiert
  • First - Line
Pembrolizumab-Monotherapie
  • NSCLC
  • metastasiert
  • First - Line
  • PD-L1 > 50%
  • nicht EGFR-Mutation
  • nicht ALK-positiv
G-BA 8/2018: beträchtlicher Zusatznutzen

first-line Studien

 First-Line randomiierte Studien mit PD-1/PD-L1 Inhibitoren beim NSCLC
Studie Population Design Primärer Endpunkt ClinicalTrials.gov Identi fier
CheckMate 026 PD-L1 – positives NSCLC Nivolumab v platinum doublet Chemotherapie PFS* NCT02041533
CheckMate 227 PD-L1 – positives and PD-L1 – negative NSCLC Kohorten
 PD-L1 – positive Kohorte: nivolumab v nivolumab- ipilimumab v platinum doublet Chemotherapie OS, PFS /td> NNCT02477826
PD-L1 – negative Kohorte: nivolumab-ipilimumab v nivolumab plus platinum doublet v platinum doublet Chemotherapie
KEYNOTE 024/td> PPD-L1 – positives NSCLC Pembrolizumab v platinum doublet Chemotherapie PFS /td> NCT02142738
KEYNOTE 042 PPD-L1 – positives NSCLC Pembrolizumab v platinum doublet Chemotherapie OS /td> NCT02220894
KEYNOTE 189 Nonsquamous NSCLC Platinum-pemetrexed with or without pembrolizumab PFS NCT02578680
IMpower 110 PPD-L1 – positives nonsquamous NSCLC Atezolizumab v platinum-pemetrexed /td> PFS NCT02409342
IMpower 111 PPD-L1 – positives squamous NSCLC Atezolizumab v platinum-gemcitabine /td> PFS NCT02409355
IMpower 130 Nonsquamous NSCLC Atezolizumab, carboplatin, and NAB-paclitaxel v carboplatin and NAB-paclitaxel PFS NCT02367781
IMpower 131 Squamous NSCLC Atezolizumab, carboplatin, and NAB-paclitaxel v atezolizumab, carboplatin, and paclitaxel v carboplatin and NAB-paclitaxel PFS NCT02367794
IMpower 150 Nonsquamous NSCLC Atezolizumab, carboplatin, and paclitaxel with or without bevacizumab v carboplatin, paclitaxel, and bevacizumab PFS NCT02366143
MYSTIC NNSCLC Durvalumab v durvalumab-tremelimumab v platinum doublet Chemotherapie PFS /td> NCT02453282
NEPTUNE NNSCLC Durvalumab-tremelimumab v platinum doublet Chemotherapie OS NCT02542293

Teil von

 Therapie des NSCLC NSCLC Tumoren des Thorax Onkologie

Quellen

 1.) Brahmer J, Reckamp KL, Baas P, et al.:
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.
N Engl J Med 2015;373:123-135

2.) Borghaei H, Paz-Ares L, Horn L, et al.:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
N Engl J Med 2015;373:1627-1639

3.) Herbst RS, Baas P, Kim DW, et al.:
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial.
Lancet 2016;387:1540-1550
4.) Fehrenbacher L, Spira A, Ballinger M, et al.:
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial.
Lancet 2016;387:1837-1846

5.) Thatcher N, Hirsch FR, Luft AV, et al.:
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial.
Lancet Oncol 2015;16:763-774

6.) Gettinger S, Rizvi NA, Chow LQ, et al.:
Nivolumab monotherapy for fi rst-line treatment of advanced non – small-cell lung cancer.
J Clin Oncol 2016;34:2980-2987

7.) Rizvi NA, Hellmann MD, Brahmer JR, et al.:
Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non – small-cell lung cancer.
J Clin Oncol 2016;34:2969-2979

8.) Papadimitrakopoulou V, Patnaik A, Borghaei H, et al.:
Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohorts A and C.
J Clin Oncol 2015;33 Suppl: Abstr 8031

Impressum                             Zuletzt geändert am 02.01.2016 16:13